From the ∗Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University

†Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance

‡Shijiazhuang Huabei Pharmaceutical Hospital of North China Medical and Health Group, Shijiazhuang, Hebei, China.

Received for publication August 12, 2023; revision accepted September 5, 2023.

T.L. and Z.L. contributed equally to this work.

Conflicts of interest and sources of funding: none declared. This study was financially supported by the Health Commission of Hebei Province in China (20160227).

Informed consent and ethical approval: This study was approved by the institutional review committee of our hospital (no. 2021069), and written informed consent was obtained from the patient.

Correspondence to: Jingmian Zhang, MD, PhD, Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang St, Chang’an District, Shijiazhuang, Hebei 050011, China. E-mail: [email protected]; or Xinming Zhao, MD, PhD, Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang St, Chang’an District, Shijiazhuang, Hebei 050011, China. E-mail: [email protected].